[Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)].
1. An improvement of the chemotherapy of hepatocellular carcinoma with adriamycin or 5-fluorouracil and a reduction of side effects has been achieved by intra-arterial administration of the drugs. This treatment provides a somewhat extended survival but no cure. 2. The treatment of hepatocellular carcinoma in patients by reduction of an inactive precursor of a cytocidal alkylating agent by azoreductase of the tumor showed no therapeutic effect. 3. A selective hepatocellular uptake of drugs coupled to asialoglycoproteins has been described. An application of this concept for the chemotherapy of hepatocellular carcinoma seems doubtful since a loss of binding proteins for desialylated glycoproteins during experimental hepatocarcinogenesis has been demonstrated. 4. The increased uptake of 5-fluorouridine in hepatomas after induction of a tissue-specific depletion of uridine 5'-triphosphate and cytidine 5'-triphosphate provides an effective experimental chemotherapy with limited side effects. A clinical use of this new concept for the chemotherapy of hepatocellular carcinoma may serve as a useful approach.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001212:Asialoglycoproteins; D001391:Azo Compounds / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000201:enzymology; D002463:Cell Membrane Permeability / Q000187:drug effects; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004789:Enzyme Activation / Q000187:drug effects; D005472:Fluorouracil / Q000627:therapeutic use; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D009247:NADH, NADPH Oxidoreductases / Q000378:metabolism; D009601:Nitroreductases; D011742:Pyrimidine Nucleotides / Q000037:antagonists & inhibitors; D014529:Uridine / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001212:Asialoglycoproteins; D001391:Azo Compounds; D006023:Glycoproteins; D011742:Pyrimidine Nucleotides; C001943:5-fluorouridine; D004317:Doxorubicin; D009247:NADH, NADPH Oxidoreductases; D009601:Nitroreductases; C021106:azoreductase; D005472:Fluorouracil; D014529:Uridine
Ansätze zur selektiven Chemotherapie des hepatozellulären Karzinoms.